Jen has represented large multinational companies in the following global corporate reorganizations:

  • The acquisition and integration of a life science business valued at $21B for a US public company
  • A global reorganization with significant regulatory implications for a Fortune 100 company, the value of which exceeded $2 billion
  • The post-acquisition integration of operations involving 40 jurisdictions and multiple disciplines for a Fortune 100 company, the transaction value of which exceeded US$5.5 billion
  • A carve out of a US public company’s digital finishing business to private equity across 8 jurisdictions
  • A global legal entity rationalization across North America, South America, and Asia for a Fortune 500 financial services company
  • The post-acquisition integration of operations across multiple jurisdictions in Asia for a leading biopharmaceutical solutions company
  • The ongoing corporate implementation of cross border transactions for a large public conglomerate